GTBP
GT Biopharma, Inc.NASDAQHealthcare$0.45-1.00%ClosedMarket Cap: $4.7M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.42
P/S
0.00
EV/EBITDA
0.06
DCF Value
$1.11
FCF Yield
-273.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-898.4%
ROA
-349.8%
ROIC
-214.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-5.6M | $-23.0M | $-4.97 | — |
| FY 2025 | $0.00 | NaN% | $-12.4M | $-28.4M | $-6.25 | — |
| Q3 2025 | $0.00 | NaN% | $-3.4M | $-3.1M | $-0.83 | — |
| Q2 2025 | $0.00 | NaN% | $-1.5M | $-1.4M | $-0.55 | — |
| Q1 2025 | $0.00 | NaN% | $-1.9M | $-776.0K | $-0.33 | — |
| Q4 2024 | $0.00 | NaN% | $-3.8M | $-3.8M | $-1.99 | — |
| FY 2024 | $0.00 | NaN% | $-14.4M | $-13.2M | $-6.94 | — |
| Q3 2024 | $0.00 | NaN% | $-3.6M | $-3.4M | $-1.53 | — |
| Q2 2024 | $0.00 | NaN% | $-3.9M | $-3.7M | $-2.17 | — |
| Q1 2024 | $0.00 | NaN% | $-3.1M | $-2.3M | $-1.64 | — |
| Q4 2023 | $0.00 | NaN% | $-3.2M | $-3.0M | $-2.15 | — |
| FY 2023 | $0.00 | NaN% | $-13.6M | $-7.6M | $-5.64 | — |